These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26830393)

  • 1. Modeling the course and outcomes of multiple sclerosis is statistical twaddle--Yes.
    Taylor BV
    Mult Scler; 2016 Feb; 22(2):140-2. PubMed ID: 26830393
    [No Abstract]   [Full Text] [Related]  

  • 2. Modeling the course and outcomes of MS is statistical twaddle--No.
    Bergamaschi R; Montomoli C
    Mult Scler; 2016 Feb; 22(2):142-4. PubMed ID: 26830394
    [No Abstract]   [Full Text] [Related]  

  • 3. Does benign multiple sclerosis today imply benign multiple sclerosis tomorrow?: implications for treatment.
    Pittock SJ
    Neurology; 2007 Feb; 68(7):480-1. PubMed ID: 17296911
    [No Abstract]   [Full Text] [Related]  

  • 4. Multiple sclerosis relapse phenotype is an important, neglected, determinant of disease outcome - YES.
    Scott TF
    Mult Scler; 2015 Oct; 21(11):1369-71. PubMed ID: 26438303
    [No Abstract]   [Full Text] [Related]  

  • 5. Reconsidering clinical outcomes in Multiple Sclerosis: relapses, impairment, disability and beyond.
    D'Souza M; Kappos L; Czaplinski A
    J Neurol Sci; 2008 Nov; 274(1-2):76-9. PubMed ID: 18817932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evoked potentials are of little use in the diagnosis or monitoring of MS: yes.
    McGuigan C
    Mult Scler; 2013 Dec; 19(14):1820-1. PubMed ID: 24277732
    [No Abstract]   [Full Text] [Related]  

  • 7. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models.
    Richards RG; Sampson FC; Beard SM; Tappenden P
    Health Technol Assess; 2002; 6(10):1-73. PubMed ID: 12022938
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcome measures in multiple sclerosis clinical trials.
    Andersson PB; Goodkin DE
    Baillieres Clin Neurol; 1997 Oct; 6(3):409-28. PubMed ID: 10101581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time?
    Schwartz CE; Quaranto BR; Healy BC; Benedict RH; Vollmer TL
    Arch Phys Med Rehabil; 2013 Oct; 94(10):1971-81. PubMed ID: 23727344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of composite scores in the quantification of deterioration in multiple sclerosis.
    Lienert C; Lechner-Scott J; Schött D; Constantinescu C; Kappos L
    Mult Scler; 1999 Aug; 5(4):220-2. PubMed ID: 10467379
    [No Abstract]   [Full Text] [Related]  

  • 11. [Impairment, disability and handicap scales in multiple sclerosis].
    Arbizu-Urdiain T; Martínez-Yélamos A; Casado Ruiz V
    Rev Neurol; 2002 Dec 1-15; 35(11):1081-93. PubMed ID: 12497316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic decision making in MS: impact of a slower disability progression.
    Pittock SJ
    Neurology; 2006 Jan; 66(2):157. PubMed ID: 16437753
    [No Abstract]   [Full Text] [Related]  

  • 13. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
    Roxburgh RH; Seaman SR; Masterman T; Hensiek AE; Sawcer SJ; Vukusic S; Achiti I; Confavreux C; Coustans M; le Page E; Edan G; McDonnell GV; Hawkins S; Trojano M; Liguori M; Cocco E; Marrosu MG; Tesser F; Leone MA; Weber A; Zipp F; Miterski B; Epplen JT; Oturai A; Sørensen PS; Celius EG; Lara NT; Montalban X; Villoslada P; Silva AM; Marta M; Leite I; Dubois B; Rubio J; Butzkueven H; Kilpatrick T; Mycko MP; Selmaj KW; Rio ME; Sá M; Salemi G; Savettieri G; Hillert J; Compston DA
    Neurology; 2005 Apr; 64(7):1144-51. PubMed ID: 15824338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age at disability milestones in multiple sclerosis and history of multiple sclerosis: a unifying concept.
    Goodin D
    Brain; 2006 Dec; 129(Pt 12):e56; author reply e57. PubMed ID: 17132635
    [No Abstract]   [Full Text] [Related]  

  • 16. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?
    Goodin DS
    Ann Neurol; 2006 Apr; 59(4):597-605. PubMed ID: 16566022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of multiple sclerosis: early prognostic factors.
    Mowry EM
    Neurol Clin; 2011 May; 29(2):279-92. PubMed ID: 21439441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age at disability milestones in multiple sclerosis.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):595-605. PubMed ID: 16415309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse, remission, and progression in multiple sclerosis.
    McDonald WI
    N Engl J Med; 2000 Nov; 343(20):1486-7. PubMed ID: 11078776
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.